Related Experiment Videos
Emerging drug therapies for benign prostatic hyperplasia
Travis L Bullock1, Gerald L Andriole
1Division of Urology, Washington University School of Medicine, St. Louis, MO 63110, USA. tlbullock@hotmail.com
Expert Opinion on Emerging Drugs
|March 1, 2006
Summary
Benign prostatic hyperplasia (BPH) causes lower urinary tract symptoms (LUTS). This review examines current BPH pharmacotherapies and highlights emerging treatments for improved patient outcomes.
Area of Science:
- Urology
- Pharmacology
- Cell Biology
Background:
- Benign prostatic hyperplasia (BPH) is a nonmalignant prostate enlargement causing lower urinary tract symptoms (LUTS).
- Historically, treatment options included watchful waiting or surgery.
- Medical therapies, including alpha-adrenergic antagonists, 5-alpha reductase inhibitors, and phytotherapies, are now prominent but have limitations.
Purpose of the Study:
- To review current pharmacotherapies for BPH-induced LUTS.
- To highlight novel and emerging drug therapies targeting BPH.
- To provide an overview of treatment options for patients with LUTS secondary to BPH.
Main Methods:
- Literature review of current and emerging BPH treatments.
- Analysis of pharmacologic agents and their mechanisms of action.
- Examination of clinical efficacy and safety profiles of existing therapies.
Main Results:
- Current medical treatments offer effective management for many patients.
- Side effects and refractoriness to existing therapies necessitate alternative options.
- Emerging therapies target novel molecular pathways within the prostate.
Conclusions:
- Pharmacotherapy plays a crucial role in managing LUTS due to BPH.
- Ongoing research is developing new treatments to address unmet needs.
- Future therapies hold promise for improved management of BPH.